Skip to main content
Premium Trial:

Request an Annual Quote

Opko to Sell $100M Shares in Public Offering

Premium

Opko Health said this week that it intends to sell $100 million of its common stock in an underwritten public offering.

Proceeds of the offering will be used for general corporate purposes, which may include research and development expenses, clinical trials, the acquisition of new technologies and businesses and other business opportunities, the company said.

Opko entered the RNAi therapeutics space with its 2007 merger with Acuity Pharmaceuticals (GSN 3/29/2007). Earlier this year, the company bought non-coding RNA drug developer Curna for $10 million (GSN 2/3/2011).

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.